Assessing tobacco use by cancer patients and facilitating cessation: an American Association for Cancer Research policy statement
- PMID: 23570694
- PMCID: PMC5992896
- DOI: 10.1158/1078-0432.CCR-13-0666
Assessing tobacco use by cancer patients and facilitating cessation: an American Association for Cancer Research policy statement
Abstract
When diagnosed with cancer, patients can immediately make a meaningful positive impact on their health by stopping their tobacco use. Scientific evidence clearly shows that tobacco use in patients with cancer leads to poorer outcomes. The specific biological processes driving tobacco consumption's interference in cancer therapy are the subject of continuing research, but the evidence is clear that tobacco use in patients with cancer leads to decreased treatment efficacy and safety, decreased survival, decreased quality of life, increased treatment-related toxicity, and increased risk of cancer recurrence and second primary tumors. Data suggest that tobacco cessation can improve outcomes and survival in patients with cancer, yet full execution of evidence-based cessation interventions is infrequent in oncology settings. Therefore, both improved provision of cessation assistance to all patients with cancer who use tobacco or have recently quit and further study of the deleterious effects of tobacco use and benefits of tobacco cessation on cancer progression and treatment are needed and recommended by the American Association for Cancer Research. Progress on both fronts begins with universal assessment and documentation of tobacco use as a standard of quality cancer care regardless of treatment setting and will be further facilitated through the development of reliable, valid, and standard measures of tobacco use, incorporation of evidence-based procedures into quality and accreditation procedures, and the development of appropriate training, clinical infrastructure, and incentives for delivery of tobacco cessation interventions.
Conflict of interest statement
The AACR takes great care to avoid any potential or actual conflicts of interest that may emanate from a personal, professional, or business interest of a member of the Writing Committee. Conflict of interest statements from the Writing Committee were obtained and are on file with the Association. The following financial relationships were disclosed: B.A. Toll received commercial research grants and support in excess of $10,000 from Pfizer for medicine only; T.H. Brandon received commercial research grants and support in excess of $10,000 from Pfizer; R.S. Herbst received consultant fees in excess of $10,000 from Biothera, Diatech, and Quintiles and less than $10,000 from N of 1. No potential conflicts of interest were reported by the other authors.
References
-
- U.S. Department of Health, Education, and Welfare. Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service. Washington, DC: PHS; 1964.
-
- Secretan B, Straif K, Baan R, Grosse Y, El Ghissassi F, Bouvard V, et al. A review of human carcinogens—Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol. 2009;10:1033–4. - PubMed
-
- Cancer prevention & early detection facts & figures. Vol. 2011 Atlanta, GA: American Cancer Society; 2011.
-
- Gellert C, Schöttker B, Brenner H. Smoking and all-cause mortality in older people: Systematic review and meta-analysis. Arch Intern Med. 2012;172:837–44. - PubMed
-
- Jha P, Ramasundarahettige C, Landsman V, Rostron B, Thun M, Anderson RN, et al. 21st-century hazards of smoking and benefits of cessation in the united states. N Engl J Med. 2013;368:341–50. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
